Navigation Links
Starpharma and Elanco Sign Agreement
Date:5/11/2009

MELBOURNE, Australia, May 11 /PRNewswire/ -- Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company.

The parties will collaborate to develop new animal health products with enhanced properties using Starpharma's dendrimer technology. Under the agreement, Starpharma will receive revenue from research fees, and is eligible for milestone payments and royalties on sale of any product developed. Elanco will receive exclusivity within the animal health field. Terms were not disclosed.

"We are very pleased to have secured such a strong animal health partner as Elanco for our delivery technology," said Dr Jackie Fairley, CEO, Starpharma.

"Their expertise, resources and market presence will be enormously valuable assets as we work to bring these innovative products to market," Fairley said. "An exciting aspect of this application for our business is that product development in the animal health sector can be faster than is usually associated with the development of human drugs."

The collaboration with Elanco is further demonstration of Starpharma's strong and successful partnership model and the multiple potential applications of its dendrimer technology. Starpharma also has partnerships with SSL International (Durex(R)), Siemens (Dade Behring), EMD Merck, Stiefel, Unilever, Qiagen and Sigma Aldrich.

Starpharma retains all rights to exploit the technology outside of Elanco's specific field of interest, including for all uses in humans, and continues to work to add to its portfolio of partners for drug delivery and dendrimer technology more widely.

In 2008, the global animal health market was reported to be about US$19 billion. Global sales are expected to reach US$21.7B by 2010, at which time the top three markets are forecast to be USA, China and Brazil, with the USA accounting for 40 percent of growth [1].

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

    For further information:

       Media
       Buchan Consulting
       Rebecca Wilson
       Tel: +61 3 9866 4722
       Mob: +61 417 382 391
       rwilson@bcg.com.au

       Ellie Papathanasiou
       Tel: +61 2 9237 2800
       epapathanasiou@bcg.com.au

       Starpharma
       www.starpharma.com
       Dr Jackie Fairley
       Chief Executive Officer
       +61 3 8532 2704

       Ben Rogers
       Company Secretary
       +61 3 8532 2702
       ben.rogers@starpharma.com

[1]Vetnosis for global animal health market estimate; all other information in "World Animal Health Markets" from Informa Healthcare, January 2008.


'/>"/>
SOURCE Starpharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
2. Heifer and Elanco Announce Charitable Partnership
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
5. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
6. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
7. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
8. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
9. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
10. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... After a ... senior finds a new lease on life with assistance from CreditAssociates. CreditAssociates provides ... their problem with unsecured debt. The senior is one of the satisfied clients ...
(Date:9/22/2017)... ... , ... “Cursed with a Curse: The Truth about Tithing”: ... experienced when breaking free from this misconception. “Cursed with a Curse: The Truth ... by Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful and ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Fruit of the Spirit: “Love””: ... exploring nature that God has created. “Fruit of the Spirit: “Love”” is the creation ... a devoted wife and mother of five. Halimah is an avid writer, her inspiration ...
(Date:9/21/2017)... ... ... With ProSlideshow Portrait from Pixel Film Studios creating a stylistic portrait slideshow ... to two layers of subject matter along with fully customizable backdrop animation, key-frameless animation, ... Pro X. , With ProSlideshow Portrait each user are given the tools and ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, Keeping Up ... , In the competitive world of drug and device marketing and promotion, drug ... FDA rules. , The FDA has issued two draft guidances that are the ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
(Date:9/7/2017)... Sept. 7, 2017  Eli Lilly and Company ... to streamline operations to more efficiently focus resources ... cost structure. Global workforce reductions, including those from ... to impact approximately 3,500 positions. ... annualized savings of approximately $500 million that will ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: